ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed stage IV non-small cell lung cancer
• * Evidence of inoperable local recurrence or metastasis
• * Bone metastases or other nonmeasurable disease may not be only evidence of metastasis
• Measurable disease documented radiographically
• No evidence of active brain metastases or leptomeningeal involvement
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1 OR
• Karnofsky 80-100%
• Life expectancy
• More than 12 weeks
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Bilirubin normal
• Alkaline phosphatase ≤ 2.5 times ULN (unless due to bone metastases and there is no radiologic evidence of hepatic metastases)
• Renal
• Creatinine ≤ 1.5 mg/dL
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception for 1 month before and during study participation
• No prior allergy or hypersensitivity to study drug
• No other concurrent active malignancy
• No pre-existing peripheral neuropathy grade 1 or greater
• No other concurrent clinically significant illness
• No concurrent serious medical risk factor involving any of the major organ systems that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No prior chemotherapy for metastatic disease
• More than 4 weeks since prior cytotoxic chemotherapy
• No concurrent doxorubicin
• No other concurrent taxanes
• No concurrent anthracyclines
• Endocrine therapy
• Not specified
• Radiotherapy
• At least 3 weeks since prior radiotherapy to a major bone marrow-containing area
• More than 4 weeks since prior radiotherapy except to a non-target lesion
• * Prior radiotherapy to a target lesion allowed provided there has been clear progression of the lesion since completion of radiotherapy
• Surgery
• Not specified
• Other
• Prior epidermal growth factor-targeted therapy allowed
• More than 4 weeks since prior investigational drugs
• No concurrent enrollment in another clinical trial in which investigational drugs are administered or investigational procedures are performed
• No concurrent treatment with any of the following:
• * Ritonavir
• * Saquinavir
• * Indinavir
• * Nelfinavir
• No concurrent anticonvulsants
• No other concurrent anticancer drugs
• No other concurrent investigational drugs